The standard annual blood panel, a basic metabolic panel, CBC, and lipid panel, was designed to detect overt disease. It will catch frank diabetes, significant anemia, or severely elevated cholesterol. It will miss the decade of subclinical dysfunction that precedes most of the chronic diseases that affect people in their 60s and 70s.
A standard panel answers whether you are sick today. Understanding where your health is headed over the next 20 years takes a different set of tests: ones that measure the mechanisms of aging and disease rather than their end-stage expressions.
This post walks through the laboratory markers worth considering for a comprehensive longevity evaluation: what each one measures, and why it matters for someone thinking about the long arc of their health. Many of these are markers we order at Aeternitas, interpreted by a physician and integrated into a written plan.
Category 1: Advanced Cardiovascular Markers
Standard cholesterol testing measures total cholesterol, HDL, LDL, and triglycerides. These are useful, but they are a blunt instrument. The following markers add the precision that careful cardiovascular risk assessment calls for.
Apolipoprotein B (ApoB)
ApoB sits in one copy on every atherogenic lipoprotein particle: every LDL, VLDL, and IDL particle that can deposit plaque in the arterial wall. It is a direct measure of atherogenic particle burden. Large cohort studies and meta-analyses find that ApoB predicts cardiovascular events at least as well as LDL-cholesterol, and tends to be more informative in patients with metabolic syndrome or insulin resistance, where LDL-C can read falsely reassuring.
ApoB goals are individualized by risk tier. A 2024 National Lipid Association expert consensus places targets below roughly 90 mg/dL for intermediate-risk patients, below 70 mg/dL for high-risk patients, and below 60 mg/dL for those at very high risk or with established cardiovascular disease. These are consensus thresholds derived from the equivalent LDL-cholesterol goals, not numbers from trials that randomized patients to an ApoB target, and the 2026 ACC/AHA dyslipidemia guideline uses ApoB to guide how hard to treat rather than publishing its own separate targets. They belong inside a full risk assessment that accounts for Lp(a), inflammatory markers, and imaging where it is available.
Lipoprotein(a), Lp(a)
Lp(a) is a genetically determined lipoprotein and an independent, causal risk factor for cardiovascular disease and calcific aortic valve stenosis. Roughly one in five people carries an elevated level, though that figure varies by ancestry and runs higher in people of African and South Asian descent. It is not meaningfully changed by diet or standard lipid-lowering therapy. Knowing your Lp(a) at least once, ideally before age 40, is worthwhile, because an elevated result changes how the rest of your risk is managed.
A high Lp(a) does not make disease inevitable. It does lower the threshold for acting on the risk factors you can change. Specific Lp(a)-lowering therapies are in late-stage clinical trials as of 2026.
High-Sensitivity CRP (hsCRP)
Chronic low-grade inflammation is associated with atherosclerotic progression, cancer risk, and accelerated aging. hsCRP is the most widely validated inflammatory marker for cardiovascular risk. A level below 1 mg/L is considered low risk; above 3 mg/L signals a meaningfully elevated inflammatory burden. Unlike LDL, hsCRP often responds to lifestyle change.
Homocysteine
Elevated homocysteine is associated with cardiovascular disease and cognitive decline, and it is influenced by B vitamin status, kidney function, and genetics. One honest caveat belongs with it: B vitamins reliably lower the number, but large randomized trials have not shown that lowering homocysteine this way reduces heart attacks or cardiovascular death, and the effect on cognitive decline is at most very small. We read it as a marker that can flag an underlying issue worth understanding, not as a number to chase for its own sake.
Category 2: Metabolic and Insulin Resistance Markers
Insulin resistance, the reduced ability of cells to respond normally to insulin, is common in adults over 40 and underlies type 2 diabetes, metabolic syndrome, cardiovascular disease, and several cancers. It is often detectable years before it shows up as elevated blood glucose, which is what makes early measurement useful.
Fasting Insulin
Fasting glucose alone is an inadequate screen for insulin resistance. Glucose can read normal while fasting insulin is elevated, meaning the pancreas is working harder to hold that glucose in range. Fasting insulin in the single digits (roughly below 5 to 7 uIU/mL) is generally reassuring; values above 10 to 12 uIU/mL suggest meaningful resistance. These are functional reference points used in longevity practice, stricter than standard lab normals, and are best interpreted by a physician rather than read as a fixed cutoff.
HOMA-IR
HOMA-IR combines fasting glucose and fasting insulin into a single calculated score that estimates insulin resistance. The common population-based cutoff is around 2.5, drawn from large national survey data; some longevity-oriented practices watch a more conservative threshold near 2.0. Either way, the number shifts with the population being studied, so it is best read alongside fasting glucose, HbA1c, and the full clinical picture rather than as a hard line.
HbA1c and Fasting Glucose
Standard markers, more useful when interpreted together with fasting insulin. A “normal” HbA1c of 5.5% paired with a fasting insulin of 15 is not a normal metabolic picture.
Triglyceride to HDL Ratio
A TG/HDL ratio above 2.0 is a simple, inexpensive marker associated with insulin resistance and a predominance of small, dense LDL particles, often more informative than either value read in isolation. It comes with a real limitation: the ratio tracks insulin resistance well in some groups and poorly in others, and it is a weak marker in Black patients in particular, so it is read in context rather than applied as one universal cutoff.
Uric Acid
Elevated uric acid is associated with insulin resistance, metabolic syndrome, hypertension, and cardiovascular disease, beyond its familiar role in gout. It is underordered and informative.
Category 3: Hormonal Markers
Hormonal shifts that begin in the 40s have downstream effects on cardiovascular health, metabolic function, cognition, bone density, and energy. A considered hormonal assessment is a core part of longevity-oriented care. The markers worth reviewing include:
- Total and free testosterone (men and women). In men, low testosterone is associated with insulin resistance, cardiovascular risk, and cognitive decline; in women, the decline through perimenopause carries its own metabolic consequences.
- Estradiol, the primary estrogen. Its decline through the perimenopause transition has direct cardiovascular and bone health implications, and it matters in men as well.
- TSH, free T3, and free T4, which together reflect thyroid function underlying metabolic rate, cardiovascular function, mood, and cognition.
Category 4: Organ Function and Nutritional Markers
Kidney and Liver Function
Creatinine, eGFR, cystatin C, ALT, AST, and GGT, read as a baseline and tracked over time. Several medications used in longevity-oriented care call for monitoring of these markers.
Vitamin D (25-OH)
Vitamin D deficiency is common and associated with cardiovascular disease, cancer risk, and immune dysfunction. The targets here are contested, and it is worth being precise about that. The long-standing sufficiency threshold is 30 ng/mL. A higher range of roughly 40 to 60 ng/mL is favored in longevity and functional-medicine practice, based largely on association data; it is not endorsed by the 2024 Endocrine Society guideline, which stepped back from routine testing and from a specific target in otherwise healthy adults. Levels above 60 ng/mL do not appear to add benefit and warrant monitoring. This is a marker to interpret individually with a physician rather than a number with one settled answer.
Omega-3 Index
The omega-3 index is the proportion of EPA and DHA in red blood cell membranes. An index below 4% is associated with elevated cardiovascular and inflammatory risk. A range of 8 to 11% is the target used in the cardiovascular research that established the measure; levels above that do not appear to add further benefit. A common worry, that a high index meaningfully raises bleeding risk, is not well supported by the evidence, which is reassuring for most people.
Complete Blood Count, Read for Longevity Signals
A standard CBC carries more than its headline numbers. Red cell distribution width (RDW) is the most established of these signals: in large population studies a higher RDW is associated with all-cause mortality, though it is a nonspecific flag that often reflects underlying inflammation or nutritional issues rather than a problem of its own. A low lymphocyte count is associated with higher mortality and offers a rough read on immune resilience. Mean platelet volume (MPV) is a softer, still-emerging marker of platelet activation. The test is routine; the interpretation is where the value sits.
Cancer Early Detection Markers
Standard tumor markers (PSA, CEA, CA-125) have limited utility for screening healthy people. Multi-cancer early detection (MCED) blood tests, such as the Galleri test, analyze cell-free DNA for cancer-associated methylation patterns and can detect signals across more than 50 cancer types. The technology is real and the specificity is high, but the case for using it to screen people without symptoms is not yet made. Overall sensitivity is moderate, around 50%, and it is lowest for early-stage disease, which is exactly where catching a cancer would help most. The largest randomized trial to date did not meet its primary goal of reducing late-stage cancers, no MCED test is FDA-approved, and a 2025 systematic review judged the evidence insufficient to weigh the benefits and harms of screening. We follow this field closely and will use these tests when the evidence supports it; today we treat them as promising rather than proven, and say so plainly.
Frequently Asked Questions
Can I order longevity labs without a doctor?
Some of these tests are available through direct-to-consumer lab services. The value, though, is in the interpretation rather than the number itself. An ApoB of 95 mg/dL means something different depending on whether your coronary calcium score is 0 or 150, whether your Lp(a) is elevated, and what your family history looks like. A physician who works in longevity medicine is what makes these results actionable.
How often should I repeat longevity labs?
Annual testing for the core metabolic and cardiovascular panel is appropriate for most people. Some markers, inflammatory markers among them, warrant more frequent testing while an intervention is underway.
What is the most important longevity blood test?
There is no single most important test; that framing misreads what comprehensive longevity medicine is. If pressed for the most underordered, highest-yield additions to a standard panel, the short list is ApoB, Lp(a), fasting insulin, and hsCRP. Most people have never had any of them measured.
Where can I get comprehensive longevity lab testing in Charlotte, NC?
Aeternitas Health offers a longevity biomarker panel that spans the categories described here, interpreted by your physician and integrated into a personalized health plan. You can learn about the evaluation day or explore membership.
About the Author
Dr. Corey Helton, MD is the founder of Aeternitas Health, a physician-led longevity and precision medicine practice in Charlotte, NC. He founded Aeternitas to practice anticipatory, data-driven medicine aimed at long-term outcomes rather than present symptoms alone. Aeternitas is a direct-pay practice with a deliberately limited panel.
References
- Soffer DE, Marston NA, Maki KC, et al. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: an expert clinical consensus from the National Lipid Association. Journal of Clinical Lipidology 2024. doi:10.1016/j.jacl.2024.08.013
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA guideline on the management of dyslipidemia. Journal of the American College of Cardiology 2026. doi:10.1016/j.jacc.2025.11.016
- Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients. Journal of the American College of Cardiology 2021;77(11):1439-1450. doi:10.1016/j.jacc.2021.01.027
- Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2022;42(1):e48-e60. doi:10.1161/ATV.0000000000000147
- Tsimikas S, Marcovina SM. Ancestry, lipoprotein(a), and cardiovascular risk thresholds. Journal of the American College of Cardiology 2022;80(9):934-946. doi:10.1016/j.jacc.2022.06.019
- Nordestgaard BG, Langsted A. Lipoprotein(a) and cardiovascular disease. Lancet 2024;404(10459):1255-1264. doi:10.1016/S0140-6736(24)01308-4
- Ridker PM. A test in context: high-sensitivity C-reactive protein. Journal of the American College of Cardiology 2016;67(6):712-723. doi:10.1016/j.jacc.2015.11.037
- Mensah GA, Arnold N, Prabhu SD, Ridker PM, Welty FK. Inflammation and cardiovascular disease: 2025 ACC scientific statement. Journal of the American College of Cardiology 2025. doi:10.1016/j.jacc.2025.08.047
- Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database of Systematic Reviews 2017;8:CD006612. doi:10.1002/14651858.CD006612.pub5
- Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. American Journal of Clinical Nutrition 2014;100(2):657-666. doi:10.3945/ajcn.113.076349
- Parcha V, Heindl B, Kalra R, et al. Insulin resistance and cardiometabolic risk profile among nondiabetic American young adults: insights from NHANES. Journal of Clinical Endocrinology and Metabolism 2022;107(1):e25-e37. doi:10.1210/clinem/dgab645
- Azarpazhooh MR, Najafi F, Darbandi M, et al. Triglyceride/high-density lipoprotein cholesterol ratio: a clue to metabolic syndrome, insulin resistance, and severe atherosclerosis. Lipids 2021;56(4):405-412. doi:10.1002/lipd.12302
- Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Archives of Internal Medicine 2005;165(12):1395-1400. doi:10.1001/archinte.165.12.1395
- Lyu D, Zhuang R, Li J, et al. Association of hyperuricemia with coronary heart disease and other cardiovascular outcomes: a systematic review and dose-response meta-analysis. PLoS One 2025;20(11):e0337091. doi:10.1371/journal.pone.0337091
- Demay MB, Pittas AG, Bikle DD, et al. Vitamin D for the prevention of disease: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2024;109(8):1907-1947. doi:10.1210/clinem/dgae290
- von Schacky C. Omega-3 index in 2018/19. Proceedings of the Nutrition Society 2020. doi:10.1017/S0029665120006989
- Salisbury AC, Harris WS, Amin AP, et al. Relation between red blood cell omega-3 fatty acid index and bleeding during acute myocardial infarction. American Journal of Cardiology 2012;109(1):13-18. doi:10.1016/j.amjcard.2011.07.063
- Tonelli M, Wiebe N, James MT, et al. Red cell distribution width associations with clinical outcomes: a population-based cohort study. PLoS One 2019;14(3):e0212374. doi:10.1371/journal.pone.0212374
- Warny M, Helby J, Nordestgaard BG, Birgens H, Bojesen SE. Incidental lymphopenia and mortality: a prospective cohort study. CMAJ 2020;192(2):E25-E33. doi:10.1503/cmaj.191024
- Kahwati LC, Avenarius M, Brouwer L, et al. Multicancer detection tests for screening: a systematic review. Annals of Internal Medicine 2025. doi:10.7326/ANNALS-25-01877
- Rubin R. These blood tests may detect dozens of cancers, but will they save lives? JAMA 2026. doi:10.1001/jama.2026.4742
Medically reviewed by Dr. Corey Helton, MD. Review date: June 2026
This article is for general educational purposes only. It is not medical advice and is not a substitute for diagnosis or treatment by a qualified physician. Reading it does not create a physician-patient relationship with Aeternitas. Talk with your own physician before making changes to your health, medications, supplements, or care.
